These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 9291171)

  • 1. Intravenous immunoglobulin (IVIG) treatment for patients with primary or secondary progressive multiple sclerosis -- outline of a double-blind randomized, placebo-controlled trial.
    Poehlau D; Federlein J; Postert T; Sailer M; Bethke F; Kappos L; Haas J; Przuntek H
    Mult Scler; 1997 Apr; 3(2):149-52. PubMed ID: 9291171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravenous immunoglobulin in primary and secondary chronic progressive multiple sclerosis: a randomized placebo controlled multicentre study.
    Pöhlau D; Przuntek H; Sailer M; Bethke F; Koehler J; König N; Heesen C; Späth P; Andresen I
    Mult Scler; 2007 Nov; 13(9):1107-17. PubMed ID: 17623736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Austrian Immunoglobulin in Multiple Sclerosis Study Group.
    Fazekas F; Deisenhammer F; Strasser-Fuchs S; Nahler G; Mamoli B
    Lancet; 1997 Mar; 349(9052):589-93. PubMed ID: 9057729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment effects of monthly intravenous immunoglobulin on patients with relapsing-remitting multiple sclerosis: further analyses of the Austrian Immunoglobulin in MS study.
    Fazekas F; Deisenhammer F; Strasser-Fuchs S; Nahler G; Mamoli B
    Mult Scler; 1997 Apr; 3(2):137-41. PubMed ID: 9291168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A double-blind, cross-over trial of intravenous immunoglobulin G in multiple sclerosis: preliminary results.
    Sørensen PS; Wanscher B; Schreiber K; Blinkenberg M; Jensen CV; Ravnborg M
    Mult Scler; 1997 Apr; 3(2):145-8. PubMed ID: 9291170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravenous immunoglobulin in secondary progressive multiple sclerosis: randomised placebo-controlled trial.
    Hommes OR; Sørensen PS; Fazekas F; Enriquez MM; Koelmel HW; Fernandez O; Pozzilli C; O'Connor P
    Lancet; 2004 Sep 25-Oct 1; 364(9440):1149-56. PubMed ID: 15451222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis.
    Ball S; Vickery J; Hobart J; Wright D; Green C; Shearer J; Nunn A; Cano MG; MacManus D; Miller D; Mallik S; Zajicek J
    Health Technol Assess; 2015 Feb; 19(12):vii-viii, xxv-xxxi, 1-187. PubMed ID: 25676540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous immunoglobulin treatment in multiple sclerosis. Effect on relapses.
    Achiron A; Gabbay U; Gilad R; Hassin-Baer S; Barak Y; Gornish M; Elizur A; Goldhammer Y; Sarova-Pinhas I
    Neurology; 1998 Feb; 50(2):398-402. PubMed ID: 9484361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of chronic progressive multiple sclerosis with intravenous immunoglobulins--interim results on drug safety of an ongoing study. IVIG study group.
    Poehlau D
    Mult Scler; 2000 Oct; 6 Suppl 2():S21-3. PubMed ID: 11188774
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ESIMS--an ongoing clinical trial in secondary progressive multiple sclerosis.
    Hommes OR; Maas-Enriquez M
    Mult Scler; 2000 Oct; 6 Suppl 2():S27-32. PubMed ID: 11188776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial.
    Fazekas F; Lublin FD; Li D; Freedman MS; Hartung HP; Rieckmann P; Sørensen PS; Maas-Enriquez M; Sommerauer B; Hanna K; ;
    Neurology; 2008 Jul; 71(4):265-71. PubMed ID: 18645164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS.
    Lancet; 1998 Nov; 352(9139):1491-7. PubMed ID: 9820296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A double-blind, placebo-controlled trial of extracorporeal photopheresis in chronic progressive multiple sclerosis.
    Rostami AM; Sater RA; Bird SJ; Galetta S; Farber RE; Kamoun M; Silberberg DH; Grossman RI; Pfohl D
    Mult Scler; 1999 Jun; 5(3):198-203. PubMed ID: 10408721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravenous immunoglobulin treatment following the first demyelinating event suggestive of multiple sclerosis: a randomized, double-blind, placebo-controlled trial.
    Achiron A; Kishner I; Sarova-Pinhas I; Raz H; Faibel M; Stern Y; Lavie M; Gurevich M; Dolev M; Magalashvili D; Barak Y
    Arch Neurol; 2004 Oct; 61(10):1515-20. PubMed ID: 15477504
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized, double-blind, placebo-controlled pilot study of i.v. immune globulins in combination with i.v. methylprednisolone in the treatment of relapses in patients with MS.
    Visser LH; Beekman R; Tijssen CC; Uitdehaag BM; Lee ML; Movig KL; Lenderink AW
    Mult Scler; 2004 Feb; 10(1):89-91. PubMed ID: 14760960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis.
    Sorensen PS; Wanscher B; Jensen CV; Schreiber K; Blinkenberg M; Ravnborg M; Kirsmeier H; Larsen VA; Lee ML
    Neurology; 1998 May; 50(5):1273-81. PubMed ID: 9595974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Austrian Immunoglobulin in MS (AIMS) study: final analysis.
    Strasser-Fuchs S; Fazekas F; Deisenhammer F; Nahler G; Mamoli B
    Mult Scler; 2000 Oct; 6 Suppl 2():S9-13. PubMed ID: 11188778
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MRI results from the European Study on Intravenous Immunoglobulin in Secondary Progressive Multiple Sclerosis (ESIMS).
    Fazekas F; Sørensen PS; Filippi M; Ropele S; Lin X; Koelmel HW; Fernandez O; Pozzilli C; O'Connor P; Enriquez MM; Hommes OR;
    Mult Scler; 2005 Aug; 11(4):433-40. PubMed ID: 16042226
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized, double-blind, placebo-controlled trial: intravenous immunoglobulin treatment in patients with diffuse cutaneous systemic sclerosis.
    Takehara K; Ihn H; Sato S
    Clin Exp Rheumatol; 2013; 31(2 Suppl 76):151-6. PubMed ID: 23910617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A multicenter, randomized, double-blind, placebo-controlled trial of high-dose intravenous immunoglobulin for oral corticosteroid-dependent asthma.
    Kishiyama JL; Valacer D; Cunningham-Rundles C; Sperber K; Richmond GW; Abramson S; Glovsky M; Stiehm R; Stocks J; Rosenberg L; Shames RS; Corn B; Shearer WT; Bacot B; DiMaio M; Tonetta S; Adelman DC
    Clin Immunol; 1999 May; 91(2):126-33. PubMed ID: 10227804
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.